2 unknown, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Papillary Renal Cell Carcinoma Type 2: new trials by email Literature Review of Papillary Renal Cell Carcinoma Type 2 trials Research Report on Papillary Renal Cell Carcinoma Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda] - Papillary Renal Cell Carcinoma Type 2 | Phase 2 | Unknown | Centre Leon Berard | 72 | 2022-06-01 | 2024-01-25 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Cabozantinib - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 35 | 2019-04-11 | 2025-08-08 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Nivolumab, Ipilimumab - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 85 | 2017-10-19 | 2022-02-16 |
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
Axitinib (1) · Ipilimumab (1) · Nivolumab (1) · cabozantinib (1) · pembrolizumab (1)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2) · Centre Leon Berard (1)
Australia (2) · France (1)